CSL (ASX:CSL) said the US government's new proclamation under section 232 of the trade expansion act on imported pharmaceuticals is unlikely to affect most of its US sales, as its plasma-derived therapies, sourced entirely from American plasma, are considered essential life-saving medicines, according to a Tuesday filing with the Australian bourse.
The company continues to invest in US manufacturing and job creation, recently revealing a $1.5 billion plan to expand its plasma therapy production in Illinois, per the filing.
The company said that the effective date for any tariff impacts is Sept. 29.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments